Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a
total that is expected to rise to about 400 million over the next 15–20 years. Most asthmatic …

Background Some patients with asthma have frequent exacerbations and persistent airflow
obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists …

An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD)
management and improving adherence with prescribed therapy is to reduce the dose …

The mainstay of current drug therapy is long-acting bronchodilators; several longer acting
inhaled β 2-agonists and muscarinic antagonists (and combinations) are now in …

Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived
series of β2-adrenoceptor agonists have been prepared and evaluated for their potential as …

The β-adrenergic signaling pathway represents a novel therapeutic target for skeletal
muscle wasting and weakness due to its role in the mechanisms controlling protein …

Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

The term ultra-LABA indicates once-daily β2-AR agonists (abediterol, indacaterol, olodaterol
and vilanterol) that are single enantiomers of the (R)-configuration. All have a near full …

A general synthesis of quinolinones and benzothiazine 1, 1-dioxides is presented. A series
of N-phenylacrylamides and N-phenylethylenesulfonamides were studied for their ability to …